What are the ingredients in the Mounjaro injection?

The active ingredient: why tirzepatide is different from other weight-loss injections

Tirzepatide is the substance doing the clinical work inside every Mounjaro pen. It is a 39-amino-acid peptide designed to bind to and activate two receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. Both receptors are involved in signalling satiety after meals, slowing the rate at which the stomach empties, and helping the body manage blood glucose. The dual-receptor action is what sets Mounjaro apart from semaglutide-based weight-loss injections, which act on the GLP-1 pathway only.

Tirzepatide was engineered to mimic the natural hormones your gut releases after eating. Once injected, it circulates for roughly a week, which is why a single weekly dose produces sustained appetite suppression across the whole dosing interval. The full Mounjaro overview explains how this mechanism translates into clinical outcomes, including the SURMOUNT-1 trial results reported in the New England Journal of Medicine.

The NHS tirzepatide medicines page provides a clear patient-level explanation of how the active ingredient works and what to expect during treatment. Worth reading before your consultation, especially if you want to ask an informed question about whether this mechanism suits your particular health picture.

The inactive ingredients in the Mounjaro KwikPen and what each one does

Knowing what the excipients are matters for a specific group of people: those with rare allergies to particular pharmaceutical agents, or those who need to confirm the formulation is suitable alongside another condition. The inactive ingredients listed in the Mounjaro SmPC (the Summary of Product Characteristics, published on the electronic Medicines Compendium) are:

Sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate act together as a buffer, holding the solution at the correct pH so tirzepatide remains chemically stable. Sodium chloride adjusts the tonicity of the solution to make it comfortable on injection. Polysorbate 80 is a widely used non-ionic surfactant that stabilises the peptide and prevents it aggregating during storage. Water for injections is the solvent. That is the complete excipient list. There are no preservatives, no animal-derived gelatin, and no latex in the pen components.

If you have a known hypersensitivity to polysorbate 80 in particular, this is something to raise during your clinical consultation before starting. A prescriber can advise whether it is safe to proceed or whether an alternative medicine is more appropriate. Details of the exact formulation are also in the Mounjaro SmPC on the eMC, which is the authoritative reference for ingredient-level queries.

How the ingredients in the Mounjaro injection influence the side-effect profile

Most of the side effects associated with Mounjaro weight-loss injections trace back to tirzepatide's activity at the GIP and GLP-1 receptors rather than to the inactive ingredients. Slowing gastric emptying and reducing appetite both have gastrointestinal consequences for some people, particularly in the early weeks. Nausea, loose stools, constipation, burping and occasional vomiting are the most commonly reported effects, and they tend to ease as the body adjusts.

The titration schedule, which starts at 2.5 mg before the prescriber steps the dose upward, exists partly to let the gut adapt gradually. Side effects after a dose increase are common and usually settle within one to two weeks. The guide to common Mounjaro injection symptoms goes into more practical detail on what to expect and what to watch for.

There are some rarer but more serious reactions that the MHRA actively monitors, including acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update reinforcing that severe stomach pain radiating to the back warrants prompt medical attention. Anyone on tirzepatide should know that sign. Because Mounjaro carries a Black Triangle (▼) status, any suspected side effects can and should be reported at the MHRA Yellow Card scheme, which helps regulators track real-world safety data.

Deciding whether to start: what the ingredient profile tells you, and what only a prescriber can

Understanding what goes into the Mounjaro KwikPen is a sensible first step, but the ingredient list alone does not settle whether treatment is right for you. A prescriber also needs to know your full medical history, any medicines you take, and whether a GLP-1/GIP mechanism is appropriate given your individual circumstances. For instance, oral contraceptive absorption may be reduced during the first four weeks at each new dose, so your prescriber will advise on adding a barrier method during that window. There are also conditions, including a personal or family history of medullary thyroid carcinoma, where tirzepatide is contraindicated entirely.

That conversation happens at the consultation stage, before any prescription is written. If you want to explore whether Mounjaro is clinically suitable for you, the right next move is to start your free consultation with one of our GPhC-registered prescribers. It is reviewed by a real clinician the same day, not processed by an algorithm. You can also read about how the Mounjaro KwikPen works or check the injection-site guidance if you want to prepare practical questions. The UK cost context for Mounjaro is available separately if that is also part of your thinking.